Introduction/Background Ovarian cancer has the highest mortality rate among gynecologic malignant tumors. Data are lacking on the survival benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with ovarian cancer who underwent primary or interval cytoreductive surgery. We aimed to assess the clinical benefit of HIPEC after primary or interval maximal cytoreductive surgery in women with stage III or IV primary advanced ovarian cancer.

Methodology A total of 194 patients with stage III or IV ovarian cancer who underwent cytoreductive surgery (CRS) were included in the study. Sixty-five patients underwent cytoreductive surgery with HIPEC using cisplatin (80 mg/m2 for 60 min at 42 °C), carboplatin (800 mg/m2 for 60 min at 42 °C), or mitomycin (35 mg/m2 for 60 min at 42 °C), 129 patients underwent cytoreductive surgery alone.

Results There was no significant difference between baseline characteristics of two groups. The groups were similar in terms of stage and residual disease (table 1). The rates of intraoperative complications were similar. The rate of postoperative complication (all grade) was higher in HIPEC group than CRS only (p=0.036). Grade 3–4 complication rates were similar. Operation time was longer in the HIPEC group (p<0.00).

Conclusion The addition of HIPEC to cytoreductive surgery is feasible and safe with acceptable intraoperative complication risk and postoperative morbidity risk in advanced stage ovarian cancer patients.

Disclosures All authors declare that there are no conflicts of interest involved with the presented data.